NSPR — InspireMD Income Statement
0.000.00%
Last trade - 00:00- $79.66m
- $16.25m
- $7.01m
- 30
- 24
- 27
- 15
Annual income statement for InspireMD, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.48 | 4.5 | 5.17 | 6.21 | 7.01 |
| Cost of Revenue | |||||
| Gross Profit | 0.083 | 0.754 | 1.12 | 1.81 | 1.51 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 12.9 | 19.2 | 23.9 | 27.3 | 40.5 |
| Operating Profit | -10.4 | -14.7 | -18.7 | -21.1 | -33.5 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.5 | -14.9 | -18.5 | -19.9 | -31.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.5 | -14.9 | -18.5 | -19.9 | -32 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -10.5 | -14.9 | -18.5 | -19.9 | -32 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.5 | -14.9 | -18.5 | -19.9 | -32 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.97 | -2.03 | -2.35 | -0.821 | -0.763 |